Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Bayer’s Stroke Drug Achieves Breakthrough Trial Results, Boosting Market Confidence 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Korea Ginseng Corp. said that a collaborative research team that it co-supports with Konyang University has found a potential mechanism in red ginseng polysaccharides that reduces cognitive decline in Alzheimer's disease.
The mechanism that red ginseng polysaccharides are related to synaptic and mitochondrial pathways in Alzheimer's disease was identified in this year’s research.
With an analysis of the protein-protein interaction of 111 proteins significantly changed by injecting red ginseng polysaccharide in mice, the research team found that the protein interaction decreased significantly.
Bioinformatics analysis confirmed that these proteins play an important role in nerve and synaptic development and function related to Alzheimer's disease, contributing to the preservation of mitochondrial forms.
How red ginseng polysaccharides do this was not fully clarified due to a lack of research two years ago.
"This study is meaningful because it has confirmed the possibility of red ginseng polysaccharides as candidates for effective treatments of Alzheimer's disease in animal models,” said Moon Min-ho, a professor at the College of Medicine at Konyang University.
In 2021, Konyang University’s Research Institute for Dementia Science, led by Professor Moon Min-ho, and Korea Ginseng Corporation's Research Institute team, led by Lee Yong-yook, announced in the international scientific journal Free Radical Biology and Medicine that red ginseng polysaccharide inhibits amyloid beta aggregation.
Alzheimer's occurs when amyloid beta, a proposed cause of Alzheimer's, aggregates and accumulates in the brain.
